Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Diagnos ( (TSE:ADK) ) has provided an update.
Diagnos Inc. has announced an amendment to the terms of its $120,000 unsecured convertible debentures, extending the maturity date from March 25, 2025, to March 25, 2026, and increasing the yearly interest rate from 8% to 10% for the extended period. This amendment is subject to TSX Venture Exchange acceptance and formal documentation, potentially impacting the company’s financial strategy and investor relations.
More about Diagnos
DIAGNOS Inc. is a Canadian corporation focused on the early detection of critical eye-related health issues. Utilizing Artificial Intelligence, the company aims to enhance diagnostic accuracy, streamline healthcare workflows, and improve patient outcomes globally.
YTD Price Performance: -6.67%
Average Trading Volume: 208,323
Technical Sentiment Signal: Buy
Current Market Cap: C$28.52M
See more insights into ADK stock on TipRanks’ Stock Analysis page.